ANRO
Alto Neuroscience
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Alto Neuroscience initiated a Phase 2b trial of ALTO-207 for treatment-resistant depressionApr 21, 2026
- Alto Neuroscience reported Phase 2 proof-of-concept topline data for ALTO-101 and highlighted pipeline progressApr 2, 2026
- Alto Neuroscience receives FDA fast track designation for ALTO-101 for treatment of cognitive impairment associated with schizophreniaOct 3, 2025